ARTICLE | Clinical News

Nypta tideglusib: Completed Phase IIb enrollment

January 23, 2012 8:00 AM UTC

Noscira completed enrollment of 308 patients with mild to moderate AD in the double-blind, placebo-controlled, European Phase IIb ARGO trial evaluating once-daily 500 and 1,000 mg oral Nypta tideglusib and 1,000 mg Nypta given every other day for 26 weeks. The trial includes a 15-month extension. ...